Faron Pharmaceuticals H1 - Advancing to registrational trials

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report. While the report did not include any major surprises, the company managed to maintain a relatively low OPEX despite concluding its BEXMAB study. Backed by encouraging clinical data and positive feedback from the FDA, we believe that the company is well-positioned for the upcoming pivotal study and a potential license deal.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/